New inhibitors of prion replication that target the amyloid precursor

Journal of General Virology

Volumn 90, Issue 5, 2009, Pages 1294-1301

  Charvériat, Mathieu ^a   Reboul, Marlène ^a   Wang, Qian ^b   Picoli, Christèle ^a   Lenuzza, Natacha ^a   Montagnac, Alain ^b   Nhiri, Naima ^b   Jacquet, Eric ^b   Guéritte, Françoise ^b   Lallemand, Jean Yves ^b   Desles, Jean Philippe ^a   Mouthon, Frank ^a  

^a INSTITUT DE RADIOPROTECTION ET DE SÛRETÉ NUCLÉAIRE   (France)

^b CNRS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINO 20 N METHYLACETAMIDO 5A PREGNANE; CHONEMORPHINE; CONESSINE DIOXALATE; CYCLOVIROBUXEINE; IREHDIAMINE E; IREHDIAMINE I; ISOFUNTUMIDINE; MBBAO ERYTHROMYCIN; PRION PROTEIN; PRION PROTEIN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; AMYLOID PRECURSOR PROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL FREE SYSTEM; CELL LINE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG STRUCTURE; IN VITRO STUDY; MOUSE; NONHUMAN; PRION; PRIORITY JOURNAL; PROTEIN METABOLISM; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; VIRUS REPLICATION; ANIMAL; BIOASSAY; DRUG ANTAGONISM; DRUG EFFECT; METHODOLOGY; MOLECULAR LIBRARY; PHYSIOLOGY;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BIOLOGICAL ASSAY; CELL LINE; MICE; PRIONS; SMALL MOLECULE LIBRARIES;

EID: 67449102109     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.009084-0     Document Type: Article

References (44)

1. Aguib, Y., Gilch, S., Krammer, C., Ertmer, A., Groschup, M. H. & Schätzl, H. M. (2008). Neuroendocrine cultured cells counteract persistent prion infection by down-regulation of PrPc. Mol Cell Neurosci 38, 98-109.
2. Bach, S., Talarek, N., Andrieu, T., Vierfond, J. M., Mettey, Y., Galons, H., Dormont, D., Meijer, L., Cullin, C. & Blondel, M. (2003). Isolation of drugs active against mammalian prions using a yeastbased screening assay. Nat Biotechnol 21, 1075-1081.
3. Bach, S., Tribouillard, D., Talarek, N., Desban, N., Gug, F., Galons, H. & Blondel, M. (2006). A yeast-based assay to isolate drugs active against mammalian prions. Methods 39, 72-77.
4. Bate, C., Salmona, M., Diomede, L. & Williams, A. (2004). Squalestatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 279, 14983-14990.
5. Bertsch, U., Winklhofer, K. F., Hirschberger, T., Bieschke, J., Weber, P., Hartl, F. U., Tavan, P., Tatzelt, J., Kretzschmar, H. A. & Giese, A. (2005). Systematic identification of antiprion drugs by high-throughput screening based on scanning for intensely fluorescent targets. J Virol 79, 7785-7791.
6. Breydo, L., Bocharova, O. V. & Baskakov, I. V. (2005). Semiautomated cell-free conversion of prion protein: Applications for high-throughput screening of potential antiprion drugs. Anal Biochem 339, 165-173.
7. Brown, P. (2007). Creutzfeldt-Jakob disease: Reflections on the risk from blood product therapy. Haemophilia 13, 33-40.
8. Sc and delays onset of prion disease. EMBO J 20, 3957-3966.
9. Gilch, S., Kehler, C. & Schätzl, H. M. (2006). The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci 31, 346-353.
10. Sc degradation. Vet Microbiol 123, 377-386.
11. Goni, F., Prelli, F., Schreiber, F., Scholtzova, H., Chung, E., Kascsak, R., Brown, D. R., Sigurdsson, E. M., Chabalgoity, J. A. & Wisniewski, T. (2008). High titers of mucosal and systemic anti-PrP antibodies abrogate oral prion infection in mucosal-vaccinated mice. Neuroscience 153, 679-686.
12. Grassi, J., Comoy, E., Simon, S., Créminon, C., Frobert, Y., Trapmann, S., Schimmel, H., Hawkins, S. A., Moynagh, J. & other authors (2001). Rapid test for the preclinical postmortem diagnosis of BSE in central nervous system tissue. Vet Rec 149, 577-582.
13. Heal, W., Thompson, M. J., Mutter, R., Cope, H., Louth, J. C. & Chen, B. (2007). Library synthesis and screening: 2,4-diphenylthiazoles and 2,4-diphenyloxazoles as potential novel prion disease therapeutics. J Med Chem 50, 1347-1353.
14. Kawatake, S., Nishimura, Y., Sakaguchi, S., Iwaki, T. & Doh-ura, K. (2006). Surface plasmon resonance analysis for the screening of antiprion compounds. Biol Pharm Bull 29, 927-932.
15. Knowles, T. P. & Zahn, R. (2006). Enhanced stability of human prion proteins with two disulfide bridges. Biophys J 91, 1494-1500.
16. Kocisko, D. A., Baron, G. S., Rubenstein, R., Chen, J., Kuizon, S. & Caughey, B. (2003). New inhibitors of scrapie-associated prion protein formation in a library of 2000 drugs and natural products. J Virol 77, 10288-10294.
17. Kocisko, D. A., Engel, A. L., Harbuck, K., Arnold, K. M., Olsen, E. A., Raymond, L. D., Vilette, D. & Caughey, B. (2005). Comparison of protease-resistant prion protein inhibitors in cell cultures infected with two strains of mouse and sheep scrapie. Neurosci Lett 388, 106-111.
18. -ΔΔCt method. Methods 25, 402-408.
19. Lorenzen, S., Dunkel, M. & Preissner, R. (2005). In silico screening of drug databases for TSE inhibitors. Biosystems 80, 117-122.
20. Magalhães, A. C., Baron, G. S., Lee, K. S., Steele-Mortimer, O., Dorward, D., Prado, M. A. & Caughey, B. (2005). Uptake and neuritic transport of scrapie prion protein coincident with infection of neuronal cells. J Neurosci 25, 5207-5216.
21. McCutchen, S. L., Colon, W. & Kelly, J. W. (1993). Transthyretin mutation Leu-55-Pro significantly alters tetramer stability and increases amyloidogenicity. Biochemistry 32, 12119-12127.
22. Outram, G. W., Dickinson, A. G. & Fraser, H. (1974). Reduced susceptibility to scrapie in mice after steroid administration. Nature 249, 855-856.
23. Pellarin, R. & Caflisch, A. (2006). Interpreting the aggregation kinetics of amyloid peptides. J Mol Biol 360, 882-892.
24. Prior, M., Lehmann, S., Sy, M. S., Molloy, B. & McMahon, H. E. (2007). Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J Virol 81, 11195-11207.
25. Reddy, T. R., Mutter, R., Heal, W., Guo, K., Gillet, V. J., Pratt, S. & Chen, B. (2006). Library design, synthesis, and screening: pyridine dicarbonitriles as potential prion disease therapeutics. J Med Chem 49, 607-615.
26. Rezaei, H., Marc, D., Choiset, Y., Takahashi, M., Hui Bon Hoa, G., Haertlé, T., Grosclaude, J. & Debey, P. (2000). High yield purification and physico-chemical properties of full-length recombinant allelic variants of sheep prion protein linked to scrapie susceptibility. Eur J Biochem 267, 2833-2839.
27. Rezaei, H., Choiset, Y., Debey, P., Grosclaude, J. & Haertlé, T. (2003). Study of stability of variants of ovine prions with different susceptibilities to scrapie. J Therm Anal Calorim 71, 237-247.
28. Ross, C. A. & Poirier, M. A. (2004). Protein aggregation and neurodegenerative disease. Nat Med 10 (Suppl.), S10-S17.
29. Rothberg, K. G., Ying, Y. S., Kamen, B. A. & Anderson, R. G. (1990). Cholesterol controls the clustering of the glycophospholipid-anchored membrane receptor for 5-methyltetrahydrofolate. J Cell Biol 111, 2931-2938.
30. Schätzl, H. M., Laszlo, L., Holtzman, D. M., Tatzelt, J., DeArmond, S. J., Weiner, R. I., Mobley, W. C. & Prusiner, S. B. (1997). A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis. J Virol 71, 8821-8831.
31. Senisterra, G. A., Soo Hong, B., Park, H. W. & Vedadi, M. (2008). Application of high-throughput isothermal denaturation to assess protein stability and screen for ligands. J Biomol Screen 13, 337-342.
32. c, in cultured cells. J Biol Chem 270, 30221-30229.
33. Song, C. H., Furuoka, H., Kim, C. L., Ogino, M., Suzuki, A., Hasebe, R. & Horiuchi, M. (2008). Effect of intraventricular infusion of anti-prion protein monoclonal antibodies on disease progression in prion-infected mice. J Gen Virol 89, 1533-1544.
34. Stahl, N., Borchelt, D. R., Hsiao, K. & Prusiner, S. B. (1987). Scrapie prion protein contains a phosphatidylinositol glycolipid. Cell 51, 229-240.
35. Stewart, L. A., Rydzewska, L. H., Keogh, G. F. & Knight, R. S. (2008). Systematic review of therapeutic interventions in human prion disease. Neurology 70, 1272-1281.
36. Sc in vitro. J Mol Biol 300, 1309-1322.
37. Taraboulos, A., Scott, M., Semenov, A., Avrahami, D., Laszlo, L. & Prusiner, S. B. (1995). Cholesterol depletion and modification of COOH-terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 129, 121-132.
38. Tatzelt, J., Prusiner, S. B. & Welch, W. J. (1996). Chemical chaperones interfere with the formation of scrapie prion protein. EMBO J 15, 6363-6373.
39. Trevitt, C. R. & Collinge, J. (2006). A systematic review of prion therapeutics in experimental models. Brain 129, 2241-2265.
40. Tucker, S., Ahl, M., Bush, A., Westaway, D., Huang, X. & Rogers, J. T. (2005). Pilot study of the reducing effect on amyloidosis in vivo by three FDA pre-approved drugs via the Alzheimer's APP 5′ untranslated region. Curr Alzheimer Res 2, 249-254.
41. Vey, M., Pilkuhn, S., Wille, H., Nixon, R., DeArmond, S. J., Smart, E. J., Anderson, R. G., Taraboulos, A. & Prusiner, S. B. (1996). Subcellular colocalization of the cellular and scrapie prion proteins in caveolae-like membranous domains. Proc Natl Acad Sci U S A 93, 14945-14949.
42. Vilette, D., Andreoletti, O., Archer, F., Madelaine, M. F., Vilotte, J. L., Lehmann, S. & Laude, H. (2001). Ex vivo propagation of infectious sheep scrapie agent in heterologous epithelial cells expressing ovine prion protein. Proc Natl Acad Sci U S A 98, 4055-4059.
43. Sc and the screening of antiprion compounds. FEBS Lett 503, 41-45.
44. Wuertzer, C. A., Sullivan, M. A., Qiu, X. & Federoff, H. J. (2008). CNS delivery of vectored prion-specific single-chain antibodies delays disease onset. Mol Ther 16, 481-486.